A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate

Inclusion Criteria:

- Diagnosis of Rheumatoid Arthritis (RA) of more than 6 months and less than 15 years

- Regular use of methotrexate (MTX) in the past 12 weeks, with the dose being stable
during the past 8 weeks

- At least 8 tender and swollen joints

- At least one erosion of a hand or foot joint observed on an X-ray

- An abnormally high C-reactive protein (CRP) level or erythrocyte sedimentation rate
(ESR)

- Positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP)
antibody

- Woman must not be pregnant, breastfeeding, or become pregnant during the study

Exclusion Criteria:

- Use of unstable doses of non-steroidal anti-inflammatory drugs (NSAIDS) in the past 6
weeks

- Steroid injection or intravenous (iv) infusion in the last 6 weeks

- Use of more than 10 milligrams/day (mg/day) of oral steroids in the last 6 weeks

- History of an inadequate response to a biologic disease-modifying anti-rheumatic drug
(DMARD)

- History of a serious reaction to other biological DMARDs

- History of the use of rituximab or other B cell therapy

- Use of DMARDS other than MTX, hydroxychloroquine, or sulfasalazine within the last 8
weeks

- Use of leflunomide within the last 12 weeks (unless cholestyramine was used to speed
up the elimination of leflunomide)

- Surgery on a joint or other major surgery less than 2 months ago, or plans to have
joint surgery or major surgery during the study

- Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease,
ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition
except RA

- Cervical cancer or squamous skin cancer within the past 3 years, or other cancer
within the past 5 years

- Received a live vaccine received within the past 12 weeks (for example, vaccines for
measles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines)

- Hepatitis or human immunodeficiency virus (HIV)

- A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months
or a serious bone or joint infection within 6 months

- Symptoms of herpes zoster or herpes simplex within the last month

- Active or latent tuberculosis (TB)

- Current symptoms of a serious disorder or illness

- Use of an investigational drug within the last month

- History of the use of rituximab, any other B cell targeted biotherapy, or denosumab